Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 3/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.31 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.31 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.31 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.31 |
| ▸ | MMP2 | P08253 | 2/20 | 0.30 |
| ▸ | MMP3 | P08254 | 1/20 | 0.30 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.30 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1665257 | 0.82 | CTSK (0.33) | ALDH1A1CTSKHCAR2PRSS1PRSS2 | |
| SCHEMBL1664112 | 0.71 | PRSS1 (0.37) | ALDH1A1CTSKHCAR2PRSS1PRSS2 | |
| SCHEMBL1664673 | 0.68 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL1664082 | 0.66 | PRSS1 (0.41) | ALDH1A1CTSKHCAR2PRSS1PRSS2 | |
| SCHEMBL1664378 | 0.64 | PRSS1 (0.41) | ALDH1A1CTSKHCAR2PRSS1PRSS2 | |
| SCHEMBL28405619 | 0.63 | ALDH1A1 (0.48) | ALDH1A1CTSKHCAR2PRSS1PRSS2 | |
| SCHEMBL28405618 | 0.63 | ALDH1A1 (0.48) | ALDH1A1CTSKHCAR2PRSS1PRSS2 | |
| SCHEMBL1663826 | 0.63 | PRSS1 (0.40) | ALDH1A1CTSKHCAR2PRSS1PRSS2 | |
| SCHEMBL19024932 | 0.62 | ALDH1A1 (0.50) | ALDH1A1HCAR2PRSS1PRSS2PRSS3 | |
| SCHEMBL19024796 | 0.62 | ALDH1A1 (0.50) | ALDH1A1HCAR2PRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011071674-A1 | ASYMMETRIC CYCLIC DIESTER COMPOUNDS | FERRO CORPORATION (US) | 2011-06-16 | — | — | WO | disclosed |
| EP-2307476-A1 | ASYMMETRIC CYCLIC DIESTER COMPOUNDS | FERRO CORPORATION (US) | 2011-04-13 | — | — | EP | disclosed |
| US-20100113664-A1 | Asymmetric Cyclic Diester Compounds | FERRO CORPORATION (US) | 2010-05-06 | — | — | US | disclosed |
| WO-2009152068-A1 | ASYMMETRIC CYCLIC DIESTER COMPOUNDS | FERRO CORPORATION (US) | 2009-12-17 | — | — | WO | disclosed |
| US-20090312470-A1 | Asymmetric Cyclic Diester Compounds | FERRO CORPORATION (US) | 2009-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312470-A1 | Asymmetric Cyclic Diester Compounds | DDT, PCNA, AADAC | ALDH1A1 585/4885CTSK 3716/4885HCAR2 1123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.